SCIENSUS PHARMA SERVICES LIMITED

Strategic Assets

Sciensus Pharma Services Limited occupies a vertically integrated niche in European pharmaceutical homecare. The company operates across manufacture of pharmaceutical preparations (SIC 21200), dispensing chemist services (SIC 47730), professional scientific and technical activities (SIC 74909), and other human health activities (SIC 86900). This combination allows it to control the pathway from medicine supply to clinical nursing administration in the patient’s home—a model that is difficult for standalone pharmacies or nursing agencies to replicate.

Its therapeutic focus on oncology, rare diseases, and long-term conditions aligns with high-value, high-complexity patient pathways where payors and manufacturers are willing to fund specialised delivery. The rebrand from Healthcare at Home to Sciensus in 2022 signals a deliberate shift toward a pan-European clinical services platform rather than a UK-only homecare provider.

Ownership is concentrated and supportive. Halcyon Acquisitions Limited and Egx Group Limited each hold more than 75% of shares and voting rights, with the right to appoint and remove directors. This concentrated sponsor base enables fast capital allocation for M&A and capital expenditure without the governance friction of dispersed shareholders. The company is current on all filings and submits full accounts, which supports credibility with lenders, regulators, and NHS counterparties.

Growth Opportunities

1. Geographic deepening across Europe. With operations already spanning the UK, Switzerland, and broader Europe, the company can replicate its homecare infusion and clinical nursing model in additional EU markets where home-based oncology and rare-disease care is under-penetrated.

2. Therapeutic expansion. Beyond cancer and rare diseases, adjacent areas such as immunology, neurology, and chronic inflammatory conditions offer similar logistics and nursing complexity, allowing the company to leverage existing infrastructure.

3. Digital and patient-support services. Integrating remote monitoring, adherence tracking, and virtual nursing triage with physical medicine delivery would increase revenue per patient and create data assets valuable to pharma manufacturers and payors.

4. Contract manufacturing and third-party services. The pharmaceutical preparation licence provides capacity that could be monetised through contract manufacturing or supply-chain services for smaller biotech firms lacking distribution infrastructure.

5. Consolidation under sponsor ownership. The >75% PSC structure positions the company as a consolidator of fragmented European homecare pharmacy and nursing providers, with the capacity to execute bolt-on acquisitions.

Strategic Risks

1. Reimbursement and regulatory dependence. Revenue is exposed to NHS and European public payor budgets. Changes in homecare reimbursement, tendering models, or medicines pricing could materially affect margins.

2. Manufacturing and supply-chain risk. Operating as a pharmaceutical manufacturer brings GMP obligations, cold-chain requirements, and pharmacovigilance duties. Any quality incident or supply disruption would directly interrupt patient treatment and carry regulatory sanction.

3. Workforce constraints. Clinical nursing and pharmacy talent are scarce and costly. Retention risk is elevated in homecare, where staff safety, travel, and on-call demands are high.

4. Competitive intensity. Large retail pharmacy chains, hospital-at-home providers, and pharmaceutical manufacturers launching direct-to-patient services could erode Sciensus’s access to patient referrals and manufacturer contracts.

5. Cross-border complexity. Operating across the UK, Switzerland, and the EU creates divergence in marketing authorisations, import/export rules, data governance, and professional registration for nurses and pharmacists.

6. Concentrated ownership. While sponsor backing is an asset, a single corporate group controlling more than 75% of voting rights means strategic direction can shift quickly with parent-company priorities, and minority stakeholders have limited oversight.